MedinCell S.A. (MEDCL.PA)
EUR 16.8
(5.53%)
EUR 16.8
(5.53%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 52.8 Million EUR | 350.97% |
| 2022 | 11.7 Million EUR | -27.95% |
| 2021 | 16.24 Million EUR | -58.41% |
| 2020 | 39.07 Million EUR | 24.9% |
| 2019 | 31.28 Million EUR | 32.5% |
| 2018 | 23.6 Million EUR | -17.72% |
| 2017 | 28.69 Million EUR | 44.38% |
| 2016 | 19.87 Million EUR | 652.2% |
| 2015 | 2.64 Million EUR | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 Q2 | 50.83 Million EUR | 0.0% |
| 2023 Q4 | 52.8 Million EUR | 0.0% |
| 2023 FY | 52.8 Million EUR | 350.97% |
| 2022 FY | 11.7 Million EUR | -27.95% |
| 2022 Q4 | 11.7 Million EUR | 0.0% |
| 2022 Q2 | 38.22 Million EUR | 0.0% |
| 2021 FY | 16.24 Million EUR | -58.41% |
| 2021 Q2 | 37.4 Million EUR | 0.0% |
| 2021 Q4 | 16.24 Million EUR | 0.0% |
| 2020 Q2 | 39.89 Million EUR | 0.0% |
| 2020 Q4 | 39.07 Million EUR | 0.0% |
| 2020 FY | 39.07 Million EUR | 24.9% |
| 2019 FY | 31.28 Million EUR | 32.5% |
| 2019 Q2 | 29.95 Million EUR | 0.0% |
| 2019 Q4 | 31.28 Million EUR | 0.0% |
| 2018 Q4 | 23.6 Million EUR | 0.59% |
| 2018 FY | 23.6 Million EUR | -17.72% |
| 2018 Q3 | 23.47 Million EUR | -10.26% |
| 2018 Q2 | 26.15 Million EUR | 0.0% |
| 2018 Q1 | 26.15 Million EUR | -8.85% |
| 2017 Q1 | - EUR | 0.0% |
| 2017 Q3 | 28.54 Million EUR | 0.0% |
| 2017 Q4 | 28.69 Million EUR | 0.51% |
| 2017 FY | 28.69 Million EUR | 44.38% |
| 2016 FY | 19.87 Million EUR | 652.2% |
| 2015 FY | 2.64 Million EUR | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| ABIONYX Pharma SA | 1.1 Million EUR | -4695.64% |
| ABIVAX Société Anonyme | 44.69 Million EUR | -18.129% |
| Adocia SA | 4.54 Million EUR | -1062.996% |
| Aelis Farma SA | 2.04 Million EUR | -2478.125% |
| Biophytis S.A. | 3.11 Million EUR | -1597.203% |
| Advicenne S.A. | 15.89 Million EUR | -232.159% |
| genOway Société anonyme | 5.51 Million EUR | -856.643% |
| IntegraGen SA | 642.28 Thousand EUR | -8120.714% |
| Medesis Pharma S.A. | 1.2 Million EUR | -4300.0% |
| Neovacs S.A. | 650 Thousand EUR | -8023.077% |
| NFL Biosciences SA | 39.2 Thousand EUR | -134583.57% |
| Plant Advanced Technologies SA | 4.35 Million EUR | -1111.98% |
| Quantum Genomics Société Anonyme | 1.96 Million EUR | -2593.425% |
| Sensorion SA | 1.24 Million EUR | -4154.939% |
| Theranexus Société Anonyme | 2.46 Million EUR | -2045.715% |
| TME Pharma N.V. | - EUR | -Infinity% |
| Valbiotis SA | 3.89 Million EUR | -1254.541% |
| TheraVet SA | 1 Million EUR | -5176.839% |
| Valerio Therapeutics Société anonyme | 6.9 Million EUR | -664.553% |
| argenx SE | 15.35 Million EUR | -243.884% |
| BioSenic S.A. | 15.57 Million EUR | -239.048% |
| Celyad Oncology SA | 902 Thousand EUR | -5753.659% |
| DBV Technologies S.A. | 4.52 Million USD | -1066.593% |
| Galapagos NV | 4.94 Million EUR | -967.961% |
| Genfit S.A. | 62.25 Million EUR | 15.185% |
| GeNeuro SA | 6.49 Million EUR | -713.271% |
| Hyloris Pharmaceuticals SA | 344 Thousand EUR | -15248.837% |
| Innate Pharma S.A. | 30.6 Million EUR | -72.51% |
| Inventiva S.A. | 25.61 Million EUR | -106.121% |
| MaaT Pharma SA | 5.42 Million EUR | -873.272% |
| Nanobiotix S.A. | 41.66 Million EUR | -26.74% |
| Onward Medical N.V. | 16.3 Million EUR | -223.807% |
| Oryzon Genomics S.A. | 3.45 Million EUR | -1430.162% |
| OSE Immunotherapeutics SA | 35.5 Million EUR | -48.699% |
| Oxurion NV | 117 Thousand EUR | -45028.205% |
| Pharming Group N.V. | 123.65 Million EUR | 57.301% |
| Poxel S.A. | 40.14 Million EUR | -31.53% |
| GenSight Biologics S.A. | 1.04 Million EUR | -4938.168% |
| Transgene SA | 17 Thousand EUR | -310488.235% |
| Financière de Tubize SA | - EUR | -Infinity% |
| UCB SA | 2.87 Billion EUR | 98.165% |
| Valneva SE | 132.76 Million EUR | 60.231% |
| Vivoryon Therapeutics N.V. | - EUR | -Infinity% |